Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
D3.181 - Oral Immunotherapy for food allergy through a personalised approach
D3.182 - Initiating Sublingual Immunotherapy in Pre-Adolescence (
D3.193 - Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders
D3.194 - Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
D3.189 - Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report
D3.183 - Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy
D3.187 - Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study
D3.188 - Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study
D3.190 - Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands
D3.191 - Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy
D3.192 - Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study
D3.385 - A Synthetic Serum Comprising Human IgE Monoclonal Antibodies to Peanut Allergens
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download